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Abstract 
Toll-like receptor 9 (TLR9) is expressed in a variety of B-cell malignancies and works as a bridge between innate and 
adaptive immunity. CpG oligodeoxynucleotides (CpG ODNs), TLR9 agonists, are able to induce anticancer immune 
responses and exert direct effects against cancer cells, serving as cancer therapeutic agents. Therefore, TLR9 might 
be a potential therapeutic target for drug development. However, several new evidences have revealed that direct 
effects of TLR9 agonists on B-cell malignancies is controversial. For example, CpG ODNs can induce apoptosis in cer-
tain type of chronic lymphocytic leukemia and lymphoma cells, while induce proliferation in multiple myeloma and 
other types of lymphoma cells. In this review, we summarize current understanding of the heterogeneity in responses 
of normal and malignant B cells to TLR9 agonists, due to differences in TLR9 expression levels, genetic alterations 
(such as MyD88 mutation), and signaling pathway activation. Especially, the downstream molecules of NF-κB signal-
ing pathway play an important role in the heterogeneous response. In order to provide possibilities for therapeutic 
manipulation of TLR9 agonists in the treatment of these disorders, the preclinical and clinical advances in using CpG 
ODNs alone and in combination therapies are also summarized in this review.
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Background
B-cell malignancies are clinically and biologically hetero-
geneous, and they comprise a diverse spectrum of acute 
or chronic leukemia and lymphoma subtypes. Over the 
last few decades, advances in chemotherapy regimens, 
monoclonal antibodies, and targeted therapies have led 
to a dramatic improvement in the treatment of these dis-
orders [1, 2]. The availability of specific antigens and the 
easy accessibility of the immune system to these diseases 
may make the immunotherapy of B-cell malignancies 
possible. Programmed cell death protein 1 (PD1) anti-
body and T cells with chimeric antigen receptors (CART) 
have been considered as promising options for treating 
B-cell malignancies. However, challenges still remain [3–
5]. For example, some drugs are known to suppress the 
immune system after long-term administration, leaving 
the patients highly susceptible to infection and relapse 
[6, 7]. Moreover, the immunotherapy of B-cell malignan-
cies is limited to only some subtypes [8, 9]. Therefore, the 
identification of novel targets in malignant B cells and the 
development of low toxicity drugs that can induce anti-
cancer immune responses as well as exert direct effects 
against cancer cells will provide new strategies for the 
treatment of B-cell malignancies.
Toll-like receptor 9 (TLR9) plays an important role in 
the innate immune system and serves as a bridge between 
innate and adaptive immunity in the antitumor responses 
[10–13]. Studies have revealed that treatment with CpG 
oligodeoxynucleotides (CpG ODNs), chemically synthe-
sized TLR9 agonists, leads to tumor regression as a result 
of T cell- or natural killer (NK) cell-dependent lysis of 
tumor cells [14]. B-cell malignancies are unique because 
they express TLR9 and directly respond to CpG ODNs. A 
recent report has demonstrated that CpG ODNs induce 
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(B-CLL) [15]. Moreover, in contrast to other immune 
adjuvants, CpG ODNs, administered as an in situ vaccina-
tion, have effects on both the immune system and B-cell 
malignancies [15–18]. Increasing evidence has shown 
that TLR9 expression on B-cell malignancies exhibits high 
heterogeneity and that the activation of TLR9 elicits the 
opposite biological effects [19–21]. For example, CpG 
ODNs induce apoptosis in some types of human Burkitt 
lymphoma [22] but enhance the proliferation of malignant 
B cells in multiple myeloma (MM) [23] and some types of 
lymphoma [10, 24]. Furthermore, some B-cell lymphomas 
have no effect during CpG stimulation [25].
The heterogeneity of TLR9 expression on B-cell malig-
nancies and their heterogeneous response to CpG ODNs 
may provide new targeted therapies against cancerous 
B cells. The responses of different cancerous B cells to 
CpG ODNs will determine the appropriate treatment 
for different B-cell malignancies. However, whether or 
not TLR9 could serve as a therapeutic target for human 
B-cell malignancies remains unknown. This review dis-
cusses the multiple roles of TLR9 signaling in B-cell 
malignancies as reported in recent preclinical and clini-
cal studies. Better understanding of the diverse roles of 
TLR9 signaling will facilitate evaluation of the potential 
utility of TLR9 as a therapeutic target in the treatment of 
B-cell malignancies.
Multiple effects of TLR9‑mediated responses
Toll-like receptors (TLRs) are important sensors of for-
eign microbial components and products of damaged or 
inflamed self-tissue. The TLRs include at least 10 types 
of integral membrane glycoproteins in humans that rec-
ognize a diverse array of ligands, including bacterial 
lipopolysaccharides, RNAs, and DNAs. Among these 
TLRs, TLR9 detects the unmethylated CpG dinucleotides 
present in viral and prokaryotic genomes, whereas these 
dinucleotides are generally methylated in host DNA [5, 
26]. TLR9 is mainly expressed in the endoplasmic retic-
ulum of human plasmacytoid dendritic cells (pDCs) and 
B cells, and induces the recruitment of myeloid differen-
tiation antigen 88 (MyD88) to initiate the activation of 
nuclear factor (NF)-κB, c-Jun N-terminal kinase (JNK), 
and p38 mitogen-activated protein kinase (MAPK) signal-
ing pathways by binding to its ligand in endocytic vesicles.
The binding of TLR9 to its ligand also activates inter-
feron regulatory factor-7, resulting in the secretion of 
type I interferons (IFNs) by pDCs and further promot-
ing pDC maturation [27–29]. Type I IFNs subsequently 
activate NK cells, natural killer T cells, monocytes, and 
induce cytotoxic lymphocyte (CTL) and T helper-1 
(Th1) responses (Fig. 1). In normal B cells, TLR9 activa-
tion increases interleukin (IL) -6 and IL-10 synthesis as 
well as cell proliferation, immunoglobulin secretion, and 
plasma cell differentiation (Fig. 1) [30–34]. Although the 
secretion of IL-10 contributes to B-cell proliferation and 
“Th1-like” isotype switch, it suppresses the antigen pres-
entation activities and the secretion of Th1-like cytokines 
(such as IL-12 and IFNs) of pDCs [34–36]. And recent 
studies indicate that TLR9 can also be expressed on the 
cell surface of B-cell lymphocytes, serving as a negative 
regulator of endosomal TLR9 activation [37].
TLR9 stimulation by CpG ODNs appears to induce a 
strong Th1-type immune response that is therapeutically 
important for antitumor and antiviral immunities. On 
the other hand, the increased expression of indoleamine 
2,3-dioxygenase in mature pDCs may result in the gen-
eration of inducible regulatory T cells (Tregs) from naive 
T cells. These Tregs play a critical role in maintaining the 
balance of the immune system [38–41] through secreting 
IL-10 and transforming growth factor-β.
TLR9 activation also leads to the upregulation of 
chemokine receptor 7, which causes cell trafficking to 
the T-cell zone of lymph nodes [42] as well as antigen-
presenting molecules (major histocompatibility com-
plex (MHC) class I and II) and costimulatory molecules 
(CD80, CD86, and CD40), thereby promoting anti-
gen presentation by pDCs and B-cells [11]. Consistent 
with these findings, a strong synergy has been reported 
between CD40 ligands and TLR9 agonists in B-cell dif-
ferentiation [43].
However, the relationship between the TLR9-mediated 
signaling pathways and cell surface molecules remains 
unclear. A limited number of experiments have shown 
that CD19 is a primary costimulatory molecule that 
amplifies B-cell receptor responses and that CpG ODNs 
induce CD19 phosphorylation through MyD88/phos-
phatidylinositol 3-kinase/AKT and Bruton’s tyrosine 
kinase (BTK) activation in human B cells [44]. Further-
more, BTK inhibitors can block the activation of CD86 
and MHC class II by CpG ODNs, suggesting the involve-
ment of BTK in the upregulation of surface molecules in 
B cells in response to CpG ODNs [45].
In sum, TLR9 mediates both positive and negative 
immune regulation, which keeps the homeostasis of the 
immune system [40, 46]. By understanding the deliberate 
regulation of TLR9 signaling pathways in immune cells as 
well as malignant B cells, it will help us facilitate manipu-
lating the immune effects of CpG ODNs, such as enhanc-
ing antitumor effects in the treatment of cancer and 
simultaneously avoiding overactive immune response.
Development of CpG ODN‑based drugs as therapeutic 
agents for B‑cell malignancies
Because of multiple immunomodulatory effects, the 
TLR9 pathway has received increasing attention for the 
development of cancer therapeutic strategies. TLR9 is 
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stimulated by its ligand-CpG motifs delivered in the 
form of CpG ODNs that are optimized for their stimula-
tory activity. These ligands can be chemically synthesized 
and used as highly selective triggers to stimulate particu-
lar subsets of immune cells. Three classes of CpG ODNs 
have been identified: Class A (Type D), Class B (Type 
K), and Class C. Class B CpG ODN (CpG-B ODN) is the 
most efficient in inducing naive B cell (CD19+CD27+) 
activation and proliferation [30]. Class C CpG ODN 
(CpG-C ODN), which exhibits characteristics of both 
Class A and Class B CpG ODNs, appears to induce more 
efficient IFN-α secretion than CpG-B ODNs [47–50]. 
Both CpG-B ODNs and CpG-C ODNs induce a potent 
Th1-based immune response, leading to comparable 
antibody production in addition to CD4+ and CD8+ 
T-cell responses.
In addition to the high effectivity of CpG-B ODNs 
for the treatment of B-cell malignancies, CpG-B ODNs 
(e.g., CpG7909 and GNKG168), as immune adjuvants, 
have demonstrated excellent safety profiles without 
Fig. 1 Roles of TLR9 in immune system regulation. CpG ODNs directly stimulate pDCs and B cells. The regulatory effects of TLR9 on the immune 
system follow a “yin-yang” principle: negative (dark segment) and positive (light segment) regulation. pDCs maturation is determined by the activa-
tion of different signaling pathways, which causes the stimulation of various cytokines and further lead to the activation of different target cells. 
For instance, CpG ODNs induce pDCs maturation by upregulation of the MHC and costimulatory molecules as well as secretion of cytokines and 
chemokines, which enhance the capability of stimulating T cells, including promoting T-cell survival and memory, enhancing CD8+ T cell cytotoxic-
ity, and activating naive CD4+ T cells. Upon TLR9 stimulation, pDCs secrete a large amount of type I IFN, which activates NK cells, NK T cells, and 
monocytes. Activated NK cells further produce IFN-γ. In addition, matured pDCs subsequently promote Th1 polarization by IL-12 production. On the 
other hand, matured pDCs increase the expression of indoleamine 2,3-dioxygenase, resulting in the generation of inducible Tregs from naive CD4+ 
T cells with potent suppressor cell function via the secretion of IL-10 and TGF-β. CpG ODNs can also promote B cell proliferation and differentiation 
into plasma cells. Moreover, TLR9 stimulation in B cells increases the secretion of cytokines such as IL-6 and IL-10
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dose-limiting, end-organ toxicity, significant laboratory 
toxicity, and severe adverse effects in over 100 clinical tri-
als. As the development of CpG-based therapy, strategies 
have been applied to maximize the therapeutic effects of 
CpG-based drugs, such as prolonging the drug half-life, 
increasing the cellular uptake and binding, enhancing 
the drug biological activity, protecting against nuclease 
degradation [51, 52]. According to the natural capability 
of certain cells to recognize CpG ODNs, CpG-siRNA/
decoyODN conjugates have been harnessed for cell-spe-
cific siRNA delivery [53, 54].
Thus, with the development of novel CpG-based 
agents, it might enhance the direct and indirect effects 
on cancer cells, which will provide more potential of CpG 
ODNs in the clinical application.
TLR9 expression and responses to CpG‑B ODNs in normal 
B‑cell subsets
B-cell differentiation, an important step in immune 
responses against invading pathogens, often involves a 
germinal center B-cell response, eventually leading to the 
generation of antibody-producing plasma cells. In addi-
tion, other subtypes of B cells, such as peripheral blood-
derived naive B cells, germinal center B cells, etc., express 
different levels of TLR9 [10, 55]. Moreover, higher levels 
of TLR9 expression are observed in tonsillar B cells than 
in circulating blood B cells [56]. These findings demon-
strate that the differentiation stage has an impact on the 
expression of TLR9 (Fig. 2). For example, memory B cells 
express higher levels of TLR9 than naive B cells or germi-
nal center B cells [10]. Some studies suggest that TLR9 
expression is related to the level of the B-cell receptor, 
whose expression is increased with the differentiation 
of B cells [57]. In addition, a recent study also has shown 
that newborn naive B cells have a higher TLR9 expression 
level than adult naive B cells [58]. Although CpG ODNs 
induce proliferation in human and murine B cells by pro-
moting the cells from G1-phase into S-phase [59, 60], the 
direct relationship between the response mediated by 
CpG ODNs and the expression of TLR9 in normal B-cell 
subsets remains elusive, and needs further study.
Heterogeneity of TLR9 expression and responses to CpG 
ODNs in B‑cell malignancies
Some B-cell malignancies are characterized by a normal 
B-cell precursor phenotype, such as CD10 expression. 
Previous studies have shown that TLR9 is expressed at 
almost all stages of B cell development [61]. Like normal 
Fig. 2 The expression of TLR9 in normal B cells and B-cell malignancies. TLR9 is expressed heterogeneously at almost all stages of B cell develop-
ment. B cell precursors (+◊) grown in Iscove’s modified Dulbecco’s media with recombinant IL-7 express different levels of TLR9. Memory B cells 
express higher levels of TLR9 (+++) than naive B cells (+) and germinal center B cells (++). In addition, B cell malignancies arising from different 
stages of B cells also express TLR9. Although the exact expression levels of TLR9 in these cells remain unknown, activation of TLR9 causes surface 
marker upregulation and cytokine secretion according to in vitro experiments (+*) and clinical data (+Δ) (CLL chronic lymphocytic leukemia, BL 
Burkitt lymphoma, NHL non-Hodgkin lymphoma, MM multiple myeloma, GC B cells germinal center B cells, FL follicular lymphoma, DLBCL diffuse 
large B cell lymphoma, MZLs marginal zone lymphomas, MCL mantle cell lymphoma, pre-B cells precursor B cells, SLL small lymphocytic lymphoma, 
ALL acute lymphocyte leukemia)
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B cells, B-cell malignancies arising from different stages 
of B cell development also express TLR9 (Fig.  2). How-
ever, recent study indicates that TLR9 expression levels of 
B-cell malignancies are different from normal B cells [62]. 
Furthermore, the TLR9 expression in malignant B cells is 
heterogeneous in each cancer subtype, even in individual 
patients. Although the heterogeneity of TLR9 expression 
in some B-cell malignancies remains to be determined, 
the degree of TLR9-mediated B-cell activation might 
depend on the expression of TLR9 in B-cell malignan-
cies [63]. However, this is not the case in some instances. 
For example, despite the same levels of TLR9 expression, 
memory B cell-related marginal zone lymphomas showed 
the higher induction of proliferation following stimula-
tion by TLR9 agonists compared to follicular lymphomas 
and diffuse large B cell lymphomas (DLBCLs) derived 
from germinal center B cells. Thus, even similar TLR9 
expression levels have different responses to TLR9 acti-
vation [64].
In addition to the differential expression of TLR9 in 
normal or cancerous B cells, heterogeneous responses 
to CpG ODNs also have been observed. Like normal B 
cells, malignant B cells exhibit heterogeneous responses 
to CpG ODNs. They can induce either proliferation or 
apoptosis of different types of cancerous B cells. Clinical 
data indicate that CpG ODNs can induce the prolifera-
tion of marginal zone lymphomas, follicular lymphomas, 
small lymphocytic lymphomas, diffuse large B cell lym-
phomas, as well as B-CLL cells from patients with pro-
gressive disease and non-mutated VH genes [65]. In 
contrast, CpG ODNs induce apoptosis of B-CLL cells 
from patients with stable disease and mutated VH genes. 
However, CpG ODNs do not have effects on some mantle 
cell lymphoma cells [63, 66].
Elucidation of the molecular mechanisms underly-
ing the heterogeneity of the TLR9 response may pro-
vide a valuable clue for the application of CpG ODNs 
in the treatment of B-cell malignancies. The TLR9 sign-
aling in malignant B cells mainly involves the NF-κB or 
MAPK signaling pathway. NF-κB, the major nuclear 
heterodimer, is expressed and activated in human pri-
mary B cells. Its activation exerts both anti-apoptotic 
and pro-apoptotic effects in response to TLR9 agonists 
stimulation [67], depending on the downstream mol-
ecules of the NF-κB signaling pathway [68]. For instance, 
if NF-κB is involved in activation of Ras-dependent 
MAPK cascades and the janus kinase/signal transducers 
and activators of transcription 3 (JAK/STAT3) signal-
ing pathway, activation will result in the proliferation of 
IL-6-processed MM [23, 69]. If NF-κB induces phospho-
rylation and activation of the signal transducer and acti-
vator of transcription 1 (STAT1) in B-CLL cells, cleavage 
and apoptosis are induced via the activation of caspases 
and poly(ADP-ribose) polymerase [15] (Fig.  3). TLR9 
responses to CpG ODNs are also associated with VH 
gene mutations. The subset of B-CLL samples without 
a VH gene mutation show strong and durable activation 
of AKT, MAPK, and NF-κB to CpG ODNs stimulation 
[65, 70]. Recent research indicates that the apoptosis of 
B-CLL cells induced by CpG ODNs can be reversed by 
IL-15- or IL-2-induced Extracellular Signal-Regulated 
Kinase (ERK) 1/2 and AKT phosphorylation as well as 
Bcl-2 upregulation [71]. This function may be associ-
ated with several chromosomal abnormalities [72]. But 
in some situation, the gene and protein expression lev-
els may also influence the outcomes of B-cell malignan-
cies upon CpG ODNs treated. For instance, associated 
with interleukin-10 stimulation, CpG ODNs drive B-cell 
lymphomas with low c-Myc expression levels prolifera-
tion through the activation of both NF-κB and STAT3 
signaling pathway and further increasing the expression 
of the cyclin-dependent kinase 4 [73]. Similarly, another 
study shows that CpG ODNs trigger sustained increases 
in NF-κB activation in mouse primary B cells, which also 
express low levels of c-Myc, thus stimulating the prolif-
eration of primary B cells and the rescue of the B cells 
from spontaneous apoptosis. However, CpG ODNs could 
induce cell apoptosis in the cells with overexpression 
of c-Myc. For example, in the mouse B-cell lymphoma 
cell line CH27, because of the high expression levels of 
c-Myc, CpG ODNs trigger a transient NF-κB activation 
eventually inducing apoptosis via Fas/Fas ligand apop-
totic pathway (Fig. 3) [74].
As a key regulator in the TLR9 signaling pathway, 
the MyD88 mutation is one of the common mutations 
in B-cell malignancies. Four MyD88 mutations, L265P 
(Mut1), S219C (Mut2), M232T (Mut4), and S243N 
(Mut5), have been reported to promote B-cell prolifera-
tion. The L265P mutation occurs in 29% of activated B 
cell-like diffuse large B-cell lymphomas, >90% of Walden-
strom’s macroglobulinemia, and other B-cell lymphoma 
patients [75]. This mutation causes uncontrolled forma-
tion of the protein complex IRAK1/4 and induction of 
Bruton’s tyrosine kinase signaling, ultimately leading to 
NF-κB overactivation, elevated levels of STAT3 phos-
phorylation, IL-6, IL-10, and IFN-β secretion, and subse-
quent enhanced survival of MyD88 L265P Waldenstrom’s 
macroglobulinemia cells [75, 76]. A clinical study is cur-
rently underway to confirm these findings [77]. In addi-
tion, mutations in the TLR/MyD88 pathway, which occur 
in 4% of CLL patients, can enhance the gene expres-
sion of the NF-κB pathway, consistent with the predic-
tion of outcome [78]. But it remains unclear whether 
MyD88 mutations impact the sensitivity of B-CLL cells 
to CpG ODNs stimulation. Therefore, further studies are 
required to determine whether mutations in TLR9 and 
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its downstream signaling pathway are correlated with dif-
ferent cancerous B cells. Even the same type of malignant 
B cells may respond differently to CpG ODNs stimula-
tion, using different downstream signaling pathways. For 
instance, Epstein–Barr virus-negative Burkitt lymphoma 
Akata31 cells exhibit more extensive apoptosis than 
Epstein–Barr virus-positive Akata cells following CpG 
2006 stimulation. This difference may be due to the sin-
gle nucleotide polymorphisms (rs5743836 and rs352140) 
within the TLR9 gene in Akata cells [22].
Malignant B cells also show heterogeneous cytokine 
secretion and costimulatory molecule expression 
responding to CpG ODNs stimulation. Following CpG 
ODNs stimulation, the expression levels of CD40, 
CD54, CD80, CD86, and MHC class I and II are all sig-
nificantly increased in B-CLL cells [11], whereas only 
the expression of CD40 is significantly upregulated in 
acute lymphocyte leukemia cells [21]. However, in man-
tle cell lymphoma cells, upregulation of CD80, CD86, and 
MHC class I is not observed. DLBCL cells also show no 
increase in the expression of MHC class I and II [63].
Fig. 3 Heterogeneous responses of normal and malignant B cells upon CpG ODNs stimulation. Activation of TLR9 results in the recruitment of 
MyD88 to initiate the activation of NF-κB, JNK, and p38 MAPK signaling pathways. Arrows represent activation. Bars represent inhibition. Activation 
of the NF-κB signaling pathway exerts both antiapoptotic and proapoptotic effects. In normal B cells (black lines), activation of NF-κB upregulates 
the expression of BCL-XL, which blocks cytochrome c release and protects B cells from apoptosis. However, upon treatment of the mouse B-cell 
lymphoma cell line CH27 with CpG ODNs, overexpression of c-Myc results in transient activation of NF-κB and subsequent inhibition of NF-κB 
activation (red bar). And then, c-Myc promotes tumor necrosis factor-induced apoptosis by decreasing BCL-XL expression and increasing FAS expres-
sion. In MM cells (purple lines), NF-κB is involved in the activation of Ras-dependent MAPK cascades and the JAK/STAT3 signaling pathway, which 
is associated with the proliferation of processed IL-6. In B-CLL cells (blue lines), activation of the NF-κB signaling pathway induces autocrine IL-10 
secretion, which further induces phosphorylation and activation of the signal transducer and activator of transcription 1, resulting in the cleavage 
and activation of caspases as well as the subsequent apoptosis of B-CLL cells (MyD88 myeloid differentiation antigen 88, IFN interferon, CLL chronic 
lymphocytic leukemia, MM multiple myeloma, MAPK mitogen-activated protein kinases, PI3K phosphatidylinositol 3-kinase, DR5 death receptor 5, 
TRAIL TNF-related apoptosis-inducing ligand, STAT1 signal transducer and activator of transcription 1)
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In summary, different cancerous B cells will respond 
differently to TLR9 stimulation because of genetic alter-
ations. The heterogeneous responses of B-cell malig-
nancies to TLR9 stimulation remain a challenge for the 
clinical application of CpG ODN-based therapies. Fur-
ther investigation is required to examine the expression 
profiles of TLR9 and the mechanisms underlying the het-
erogeneous response to TLR9 stimulation in malignant 
B cells. Characterization of these profiles and pathways 
may improve the efficacy of CpG ODNs treatment in 
combination with specific pharmacological inhibitors.
Potential therapeutic effects of CpG ODNs in B‑cell 
malignancies
Above all, the TLR9 agonists demonstrates direct 
effects on certain types of malignant cells, besides its 
stimulating effects on immune response. It has shown 
therapeutic potential of TLR9 agonists alone and in com-
bination therapies in B-cell malignancies in  vitro and 
in vivo studies.
Several clinical and preclinical trials have demonstrated 
that CpG ODNs have direct antitumor effects in mono-
therapy. For example, an in vitro study has demonstrated 
that CpG 685, a Class B CpG ODN, induces apoptosis of 
CLL cells via activation of NF-κB [15]. Moreover, a recent 
phase I study of CpG 7909 (PF-3512676) [31] in patients 
with early relapsed CLL has revealed that a multiple 
weekly subcutaneous dose of 0.45 mg/kg body weight is 
well tolerated, indicating that multi-dose direct effects 
on B-cell malignancies. Furthermore, it has no toxicity 
against normal cells and also shows its activating effects 
on immune system [64, 79].
Some studies have also shown CpG ODNs’ indirect 
effects on malignant B cells by activating antitumor 
immune responses. Intravenous administration of CpG 
7909 at dose levels 0.01–0.64 mg/kg three times a week 
was found to elicit an increased NK cell number and 
induce NK cell activation in patients with refractory non-
Hodgkin lymphoma [80]. Additionally, in some types 
of B-cell malignancy, CpG ODNs have no direct proa-
poptotic effects on the malignant B cells and only have 
immune effects in some cases. CpG ODNs have been 
shown to induce pDCs maturation to secrete IFN-α and 
IFN-λ, which results in G2-phase arrested in MM cells 
co-cultured with pDCs. Instead, there is no direct effects 
on MM cells treated with CpG ODNs alone in vitro [81–
84]. Therefore, TLR9 agonists could perform its thera-
peutic potentiality on B-cell malignancies through the 
host immune cells and/or direct effects on the tumor 
cells [17].
In addition to being an efficacious single agent, CpG 
ODNs show synergetic effects with other therapies such 
as chemotherapy, radiotherapy, and target therapy. In the 
studies of combination of CpG ODNs with chemotherapy 
agent cyclophosphamide (CTX), the combination group 
showed better outcome in the patients with lymphoma 
compared with using CpG ODNs or CTX alone. CTX 
can directly inhibit the tumor growth and give time for 
the activation of CD8+ T cells mediated by CpG ODNs. 
Moreover, CTX may inhibits the ratio of tumor-infiltrat-
ing Treg cells, so that it breaks the homeostasis of the 
immune system and further enhances the Th1 response. 
[17] These similar synergetic effects have also been dis-
covered in other types of tumors, with increased survival 
time [85–88].
Apart from improving the chemotherapeutic agents’ 
effects, CpG ODNs also improve radiotherapy outcomes 
of both immunogenic and non-immunogenic with a high 
complete tumor remission rate [17, 89] by exerting direct 
effects on human malignant B cells and indirect effects 
on the immune system with an increase in the num-
ber of tumor-reactive memory CD8+ T cells, leading to 
enhanced antitumor immunity [18, 90, 91]. Besides, the 
treatment was well tolerated. Additionally, CpG ODNs 
can protect normal B cells from irradiation-induced cell 
death and enhance macrophages viability even after irra-
diation. And this protection may be associated with the 
upregulation of anti-apoptotic molecules, such as Bcl-
xS/L and Bcl-2 in these cells [92]. Thus, it indicates that 
CpG ODNs can improve radioresistance of the normal 
immune cells.
Furthermore, CpG ODNs can increase the sensitivity 
of tumor cells to antibody-dependent cellular cytotoxic-
ity (ADCC) lysis, and potentiate cytotoxicity of ADCC 
effectors. The activation and expansion of Fc receptor-
bearing NK cells through cytokines secretion (such as 
IL-12) mediated by CpG ODNs may increase the efficacy 
of rituximab. It has been demonstrated that CpG ODNs, 
when administered in combination with the CD20 anti-
body, can enhance the efficiency of rituximab in kill-
ing Daudi non-Hodgkin lymphoma cell lines. Besides, 
the upregulation of CD20 expression levels mediated by 
CpG ODNs might further promotes the killing effects by 
rituximab [80, 93]. This effect has also been confirmed in 
murine lymphoma models. CpG ODNs also can be used 
as adjuvants for anti-idiotype vaccines to increase the 
efficiency of monoclonal antibody therapy, depending on 
the TLR9 expression in host immune cells [94, 95]. Fur-
thermore, rituximab plus intratumoral CpG ODNs, but 
not systemic CpG ODNs, eradicate up to half of 7-day 
established 38C13-huCD20 tumors, a syngeneic murine 
B cell lymphoma expressing human CD20. Additionally, 
brief and extended-duration administration of CpG 7909 
in combination with rituximab has been found to be safe 
in patients with relapsed/refractory non-Hodgkin lym-
phoma [96].
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To increase the cell specific activity, CpG-siRNA/
decoyODN conjugates provide a novel therapeutic strat-
egy. For instanse, STAT3 plays an important role in both 
cancer cells and tumor-associated immune cells to pro-
mote cancer progression and survival with upregulation 
of BCL-XL protein expression. CpG-STAT3siRNA con-
jugates shows a better effect not only on the direct kill-
ing but also on immune-mediated eradication compared 
with using CpG ODNs alone in hematologic malignan-
cies with upregulating costimulatory and proinflamma-
tory molecules, downregulating PD-L1 molecule, and 
increasing the ratio of tumor-infiltrating CD8+ T cells 
[53, 54].
In short, despite the fact that the use of CpG ODNs 
alone or in combination therapies showed a satisfac-
tory treatment effect in B-cell malignancies, CpG ODNs 
do not have proapoptotic or antitumor effects in some 
cases [84]. Thus, it suggests that the care should be taken 
regarding the application of CpG ODNs in B-cell lym-
phoma treatment. Accordingly, future studies should 
aim to elucidate the expression profiles of TLR9 in B-cell 
malignancies, develop other types of CpG ODNs, and 
design combination therapies with CpG ODNs for the 
treatment of B-cell malignancies.
Conclusion and prospects
CpG ODNs exert multiple effects on the immune sys-
tem in addition to direct effects on B-cell malignancies. 
Numerous preclinical and clinical trials have dem-
onstrated the safety and efficacy of CpG ODNs in the 
treatment of several B-cell malignancies, indicating that 
TLR9 represents a promising target for the treatment of 
such disorders. However, some studies have reported 
that CpG ODN-based therapies elicit tumor-promot-
ing effects. Therefore, the heterogeneous expression of 
TLR9 and differential effects of CpG ODNs in differ-
ent B-cell malignancies require further investigation. 
In addition, CpG ODNs act synergistically with other 
therapies, and potential combination therapeutic strate-
gies for the treatment of B-cell malignancies may thus 
achieve the desired outcomes. The use of combination 
therapies and CpG ODNs administration as an in  situ 
vaccination would maximize the clinical benefit. As a 
result, deepening the understanding of the oncogenic 
mechanisms in B-cell malignancies will enable match-
ing treatments with the cancer genotype, thus providing 
further possibilities for the therapeutic manipulation 
of TLR9 as a target for the precise treatment of B-cell 
malignancies.
Abbreviations
TLR9: Toll-like receptor 9; TLRs: Toll-like receptors; mAbs: monoclonal antibod-
ies; CpG ODN: CpG oligodeoxynucleotide; MyD88: myeloid differentiation 
antigen 88; PD1: programmed cell death protein 1; CART: T cells with chimeric 
antigen receptors; JNK: c-Jun N-terminal kinase; CTL: cytotoxic lymphocyte; 
IFN: interferon; IL: interleukin; MHC: major histocompatibility complex; Th1: 
T helper-1; NK: natural killer; ALL: acute lymphocyte leukemia; CLL: chronic 
lymphocytic leukemi; MM:  multiple myeloma; DLBCLs: diffuse large B cell 
lymphomas; pDCs: plasmacytoid dendritic cells; CTX: cyclophosphamide; NF: 
nuclear factor; MAPK: mitogen-activated protein kinases; BTK: Bruton’s tyrosine 
kinase; JAK: janus kinase/signal transducers ; ERK: Extracellular Signal-Regu-
lated Kinase; STAT3: signal transducer and activator of transcription 3; STAT1: 
signal transducer and activator of transcription 1; ADCC: antibody-dependent 
cellular cytotoxicity.
Authors’ contributions
LB carried out the primary literature search and analysis, drafted and revised 
the manuscript. WC helped the modification of the manuscript. JTC and WL 
contributed to the coordination and helped to draft the manuscript. LZ, CN, 
and WH participated in discussions and literature search. JWC carried out the 
design of the research and literature analysis, drafted and revised the manu-
script. All authors read and approved the final manuscript.
Author details
1 Cancer Center, The First Bethune Hospital of Jilin University, 71 Xinmin 
Street, Changchun 130021, China. 2 ADC Biomedical Research Institute, 1919 
University Avenue, Saint Paul, MN 55104, USA. 3 Institute of Translational 
Medicine, The First Bethune Hospital of Jilin University, 71 Xinmin Street, 




The authors declare that they have no competing interests.
Availability of data and materials
The datasets supporting the conclusions of this article are included within the 
article and its additional files.
Funding
This work was supported by the Jilin Provincial Science and Technology 
Department (Grants 20111807 and 20140414014GH, and 20150101176 to 
JWC), the Platform Construction Project of Development and Reform Com-
mission of Jilin Province (Grant 2014N147 to JWC), the Bethune Program B 
of Jilin University (Grant 2012202 to JWC), the National Major Scientific and 
Technological Special Project (Grant 2013ZX09102032 to JTC), and the Key 
Scientific Project of Jilin Province (20140204024YY to JTC).
Received: 28 November 2016   Accepted: 17 February 2017
References
 1. Arnason JE, Brown JR. Targeted therapy for chronic lymphocytic leuke-
mia: current status and future directions. Drugs. 2015;75:143–55.
 2. Rossi JF. Targeted therapies in adult B-cell malignancies. Biomed Res Int. 
2015;2015:217593.
 3. Finn OJ. Cancer vaccines: between the idea and the reality. Nat Rev 
Immunol. 2003;3:630–41.
 4. Naddafi F, Davami F. Anti-CD19 monoclonal antibodies: a new approach 
to lymphoma therapy. Int J Mol Cell Med. 2015;4:143.
 5. Bird AP. CpG-rich islands and the function of DNA methylation. Nature. 
1986;321:209–13.
 6. Berges C, Haberstock H, Fuchs D, Miltz M, Sadeghi M, Opelz G, et al. 
Proteasome inhibition suppresses essential immune functions of human 
CD4+ T cells. Immunology. 2008;124:234–46.
 7. Di Paolo JA, Huang T, Balazs M, Barbosa J, Barck KH, Bravo BJ, et al. Specific 
Btk inhibition suppresses B cell- and myeloid cell-mediated arthritis. Nat 
Chem Biol. 2011;7:41–50.
 8. Zappasodi R, de Braud F, Di Nicola M. Lymphoma immunotherapy: cur-
rent status. Front Immunol. 2015;6:448.
Page 9 of 10Bai et al. J Transl Med  (2017) 15:51 
 9. Lorentzen CL, Straten PT. CD19-chimeric antigen receptor t cells for 
treatment of chronic lymphocytic leukaemia and acute lymphoblastic 
leukaemia. Scand J Immunol. 2015;82:307–19.
 10. Chiron D, Bekeredjian-Ding I, Pellat-Deceunynck C, Bataille R, Jego G. Toll-
like receptors: lessons to learn from normal and malignant human B cells. 
Blood. 2008;112:2205–13.
 11. Jahrsdörfer B, Hartmann G, Racila E, Jackson W, Mühlenhoff L, Meinhardt 
G, et al. CpG DNA increases primary malignant B cell expression of 
costimulatory molecules and target antigens. J Leukoc Biol. 2001;69:81–8.
 12. Agrawal S, Gupta S. TLR1/2, TLR7, and TLR9 signals directly activate 
human peripheral blood naive and memory B cell subsets to produce 
cytokines, chemokines, and hematopoietic growth factors. J Clin Immu-
nol. 2011;31:89–98.
 13. Sabroe I, Parker LC, Dower SK, Whyte MKB. The role of TLR activation in 
inflammation. J Pathol. 2008;214:126–35.
 14. Maruyama K, Selmani Z, Ishii KH, Yamaguchi K. Innate immunity and 
cancer therapy. Int Immunopharmacol. 2011;11:350–7.
 15. Liang X, Moseman EA, Farrar MA, Bachanova V, Weisdorf DJ, Blazar BR, 
et al. Toll-like receptor 9 signaling by CpG-B oligodeoxynucleotides 
induces an apoptotic pathway in human chronic lymphocytic leukemia B 
cells. Blood. 2010;115:5041–52.
 16. Ren T, Xu L, Jiao S, Wang Y, Cai Y, Liang Y, et al. TLR9 signaling promotes 
tumor progression of human lung cancer cell in vivo. Pathol Oncol Res. 
2009;15:623–30.
 17. Li J, Song W, Czerwinski DK, Varghese B, Uematsu S, Akira S, et al. Lym-
phoma immunotherapy with CpG oligodeoxynucleotides requires TLR9 
either in the host or in the tumor itself. J Immunol. 2007;179:2493–500.
 18. Brody JD, Ai WZ, Czerwinski DK, Torchia JA, Levy M, Advani RH, et al. In situ 
vaccination with a TLR9 agonist induces systemic lymphoma regression: 
a phase I/II study. J Clin Oncol. 2010;28:4324–32.
 19. Rakoff-Nahoum S, Medzhitov R. Regulation of spontaneous intes-
tinal tumorigenesis through the adaptor protein MyD88. Science. 
2007;317:124–7.
 20. Swann JB, Vesely MD, Silva A, Sharkey J, Akira S, Schreiber RD, et al. 
Demonstration of inflammation-induced cancer and cancer immu-
noediting during primary tumorigenesis. Proc Natl Acad Sci USA. 
2008;105:652–6.
 21. Corthals SL, Wynne K, She K, Shimizu H, Curman D, Garbutt K, et al. 
Differential immune effects mediated by Toll-like receptors stimula-
tion in precursor B-cell acute lymphoblastic leukaemia. Br J Haematol. 
2006;132:452–8.
 22. Noack J, Jordi M, Zauner L, Alessi D, Burch A, Tinguely M, et al. TLR9 
agonists induced cell death in Burkitt’s lymphoma cells is variable and 
influenced by TLR9 polymorphism. Cell Death Dis. 2012;3:e323.
 23. Bohnhorst J, Rasmussen T, Moen SH, Fløttum M, Knudsen L, Børset M, 
et al. Toll-like receptors mediate proliferation and survival of multiple 
myeloma cells. Leukemia. 2006;20:1138–44.
 24. Henault M, Lee LN, Evans GF, Zuckerman SH. The human Burkitt 
lymphoma cell line Namalwa represents a homogenous cell system 
characterized by high levels of Toll-like receptor 9 and activation by CpG 
oligonucleotides. J Immunol Methods. 2005;300:93–9.
 25. Buhé V, Guerrier T, Youinou P, Berthou C, Loisel S. CpG ODN enhances 
the efficacy of rituximab in non-Hodgkin lymphoma. Ann NY Acad Sci. 
2009;1173:858–64.
 26. Akira S, Takeda K, Kaisho T. Toll-like receptors: critical proteins linking 
innate and acquired immunity. Nat Immunol. 2001;2:675–80.
 27. Guiducci C, Ghirelli C, Marloie-Provost MA, Matray T, Coffman RL, Liu YJ, 
et al. PI3K is critical for the nuclear translocation of IRF-7 and type I IFN 
production by human plasmacytoid predendritic cells in response to TLR 
activation. J Exp Med. 2008;205:315–22.
 28. Kumagai Y, Takeuchi O, Akira S. TLR9 as a key receptor for the recognition 
of DNA. Adv Drug Deliv Rev. 2008;60:795–804.
 29. Honda K, Takaoka A, Taniguchi T. Type I interferon [corrected] gene induc-
tion by the interferon regulatory factor family of transcription factors. 
Immunity. 2006;25:349–60.
 30. Jiang W, Lederman MM, Harding CV, Rodriguez B, Mohner RJ, Sieg SF. 
TLR9 stimulation drives naive B cells to proliferate and to attain enhanced 
antigen presenting function. Eur J Immunol. 2007;37:2205–13.
 31. Eckl-Dorna J, Batista FD. BCR-mediated uptake of antigen linked to TLR9 
ligand stimulates B-cell proliferation and antigen-specific plasma cell 
formation. Blood. 2009;113:3969–77.
 32. Von Glehn F, Santos LM, Balashov KE. Plasmacytoid dendritic cells and 
immunotherapy in multiple sclerosis. Immunotherapy. 2012;4:1053–61.
 33. Huang X, Yang Y. Targeting the TLR9-MyD88 pathway in the regulation of 
adaptive immune responses. Expert Opin Ther Targets. 2010;14:787–96.
 34. Peng SL. Signaling in B cells via Toll-like receptors. Curr Opin Immunol. 
2005;17:230–6.
 35. Krieg AM, Vollmer J. Toll-like receptors 7, 8, and 9: linking innate immunity 
to autoimmunity. Immunol Rev. 2007;220:251–69.
 36. Gray M, Gray D. Regulatory B cells mediate tolerance to apoptotic self in 
health: implications for disease. Int Immunol. 2015;27:505–11.
 37. Guerrier T, Pochard P, Lahiri A, Youinou P, Pers JO, Jamin C. TLR9 expressed 
on plasma membrane acts as a negative regulator of human B cell 
response. J Autoimmun. 2014;51:23–9.
 38. Pasare C, Medzhitov R. Toll pathway-dependent blockade of CD4+ CD25+ 
T cell-mediated suppression by dendritic cells. Science. 2003;299:1033–6.
 39. Yang Y, Huang CT, Huang X, Pardoll DM. Persistent Toll-like receptor sig-
nals are required for reversal of regulatory T cell-mediated CD8 tolerance. 
Nat Immunol. 2004;5:508–15.
 40. Conroy H, Marshall NA, Mills KHG. TLR ligand suppression or enhance-
ment of Treg cells? A double-edged sword in immunity to tumours. 
Oncogene. 2008;27:168–80.
 41. Puccetti P. On watching the watchers: IDO and type I/II IFN. Eur J Immu-
nol. 2007;37:876–9.
 42. Van Duin D, Medzhitov R, Shaw AC. Triggering TLR signaling in vaccina-
tion. Trends Immunol. 2006;27:49–55.
 43. Wagner M, Poeck H, Jahrsdoerfer B, Rothenfusser S, Prell D, Bohle B, et al. 
IL-12p70-dependent Th1 induction by human B cells requires combined 
activation with CD40 ligand and CpG DNA. J Immunol. 2004;172:954–63.
 44. Morbach H, Schickel JN, Cunningham-Rundles C, Conley ME, Reisli I, 
Franco JL, et al. CD19 controls Toll-like receptor 9 responses in human B 
cells. J Allergy Clin Immunol. 2016;137:889–98.
 45. Kenny EF, Quinn SR, Doyle SL, Vink PM, van Eenennaam H, O’Neill LA. 
Bruton’s tyrosine kinase mediates the synergistic signalling between TLR9 
and the B cell receptor by regulating calcium and calmodulin. PLoS ONE. 
2013;8:e74103.
 46. Lande R, Gilliet M. Plasmacytoid dendritic cells: key players in the initiation 
and regulation of immune responses. Ann NY Acad Sci. 2010;1183:89–103.
 47. Carpentier AF. Cancer immunotherapy with CpG-ODN. Med Sci (Paris). 
2005;21:73–7.
 48. Verthelyi D, Ishii KJ, Gursel M, Takeshita F, Klinman DM. Human peripheral 
blood cells differentially recognize and respond to two distinct CPG 
motifs. J Immunol. 2001;166:2372–7.
 49. Rothenfusser S, Tuma E, Endres S, Hartmann G. Plasmacytoid dendritic 
cells: the key to CpG. Hum Immunol. 2002;63:1111–9.
 50. Vollmer J, Weeratna R, Payette P, Jurk M, Schetter C, Laucht M, et al. 
Characterization of three CpG oligodeoxynucleotide classes with distinct 
immunostimulatory activities. Eur J Immunol. 2004;34:251–62.
 51. Mutwiri GK, Nichani AK, Babiuk S, Babiuk LA. Strategies for enhancing 
the immunostimulatory effects of CpG oligodeoxynucleotides. J Control 
Release. 2004;97:1–17.
 52. Sands H, Gorey-Feret LJ, Cocuzza AJ, Hobbs FW, Chidester D, Trainor GL. 
Biodistribution and metabolism of internally 3H-labeled oligonucleotides. 
I. Comparison of a phosphodiester and a phosphorothioate. Mol Pharma-
col. 1994;45:932–43.
 53. Hossain DMS, Dos Santos C, Zhang Q, Kozlowska A, Liu H, Gao C, et al. 
Leukemia cell–targeted STAT3 silencing and TLR9 triggering generate 
systemic antitumor immunity. Blood. 2014;123:15–25.
 54. Zhang Q, Hossain DMS, Nechaev S, Kozlowska A, Zhang W, Liu Y, et al. 
TLR9-mediated siRNA delivery for targeting of normal and malignant 
human hematopoietic cells in vivo. Blood. 2013;121:1304–15.
 55. Dorner T, Radbruch A. Antibodies and B cell memory in viral immunity. 
Immunity. 2007;27:384–92.
 56. Månsson A, Adner M, Höckerfelt U, Cardell LO. A distinct Toll-like receptor 
repertoire in human tonsillar B cells, directly activated by PamCSK, R-837 
and CpG-2006 stimulation. Immunology. 2006;118:539–48.
 57. Bernasconi NL, Onai N, Lanzavecchia A. A role for Toll-like receptors 
in acquired immunity: up-regulation of TLR9 by BCR triggering in 
naive B cells and constitutive expression in memory B cells. Blood. 
2003;101:4500–4.
 58. Pettengill MA, van Haren SD, Li N, Dowling DJ, Bergelson I, 
Jans J, et al. Distinct TLR-mediated cytokine production and 
Page 10 of 10Bai et al. J Transl Med  (2017) 15:51 
immunoglobulin secretion in human newborn naive B cells. Innate 
Immun. 2016;22:433–43.
 59. Yi AK, Chang M, Peckham DW, Krieg AM, Ashman RF. CpG oligodeoxyri-
bonucleotides rescue mature spleen B cells from spontaneous apoptosis 
and promote cell cycle entry. J Immunol. 1998;160:5898–906.
 60. Nikitin PA, Price AM, McFadden K, Yan CM, Luftig MA. Mitogen-induced 
B-cell proliferation activates Chk2-dependent G1/S cell cycle arrest. PLoS 
ONE. 2014;9:e87299.
 61. Azulay-Debby H, Edry E, Melamed D. CpG DNA stimulates autoreactive 
immature B cells in the bone marrow. Eur J Immunol. 2007;37:1463–75.
 62. Jahrsdorfer B, Mühlenhoff L, Blackwell SE, Wagner M, Poeck H, Hartmann 
E, et al. B-cell lymphomas differ in their responsiveness to CpG oligode-
oxynucleotides. Clin Cancer Res. 2005;11:1490–9.
 63. Sanchez-Cuaxospa M, Contreras-Ramos A, Perez-Figueroa E, Medina-
Sanson A, Jimenez-Hernandez E, Torres-Nava JR, et al. Low expression 
of Toll-like receptors in peripheral blood mononuclear cells of pediatric 
patients with acute lymphoblastic leukemia. Int J Oncol. 2016;49:675–81.
 64. Guerrier T, Youinou P, Pers JO, Jamin C. TLR9 drives the development of 
transitional B cells towards the marginal zone pathway and promotes 
autoimmunity. J Autoimmun. 2012;39:173–9.
 65. Longo PG, Laurenti L, Gobessi S, Petlickovski A, Pelosi M, Chiusolo P, et al. 
The Akt signaling pathway determines the different proliferative capacity 
of chronic lymphocytic leukemia B-cells from patients with progressive 
and stable disease. Leukemia. 2007;21:110–20.
 66. Zent CS, Smith BJ, Ballas ZK, Wooldridge JE, Link BK, Call TG, et al. Phase 
I clinical trial of CpG oligonucleotide 7909 (PF-03512676) in patients 
with previously treated chronic lymphocytic leukemia. Leuk Lymphoma. 
2012;53:211–7.
 67. Hartmann G, Krieg AM. Mechanism and function of a newly identified 
CpG DNA motif in human primary B cells. J Immunol. 2000;164:944–53.
 68. Farhana L, Dawson MI, Fontana JA. Apoptosis induction by a novel 
retinoid-related molecule requires nuclear factor-kappaB activation. 
Cancer Res. 2005;65:4909–17.
 69. Ogata A, Chauhan D, Teoh G, Treon SP, Urashima M, Schlossman RL, 
et al. IL-6 triggers cell growth via the Ras-dependent mitogen-activated 
protein kinase cascade. J Immunol. 1997;159:2212–21.
 70. Arvaniti E, Ntoufa S, Papakonstantinou N, Touloumenidou T, Laoutaris N, 
Anagnostopoulos A, et al. Toll-like receptor signaling pathway in chronic 
lymphocytic leukemia: distinct gene expression profiles of potential 
pathogenic significance in specific subsets of patients. Haematologica. 
2011;96:1644–52.
 71. Chatzouli M, Ntoufa S, Papakonstantinou N, Chartomatsidou E, Anagnost-
opoulos A, Kollia P, et al. Heterogeneous functional effects of concomi-
tant B cell receptor and TLR stimulation in chronic lymphocytic leukemia 
with mutated versus unmutated Ig genes. J Immunol. 2014;192:4518–24.
 72. Mongini PK, Gupta R, Boyle E, Nieto J, Lee H, Stein J, et al. TLR-9 and IL-15 
synergy promotes the in vitro clonal expansion of chronic lymphocytic 
leukemia B cells. J Immunol. 2015;195:901–23.
 73. Feist M, Kemper J, Taruttis F, Rehberg T, Engelmann JC, Gronwald W, 
et al. Synergy of interleukin 10 and Toll-like receptor 9 signalling in B 
cell proliferation: implications for lymphoma pathogenesis. Int J Cancer. 
2017;104:1147–58.
 74. Arunkumar N, Liu C, Hang H, Song W. Toll-like receptor agonists induce 
apoptosis in mouse B-cell lymphoma cells by altering NF-kappaB activa-
tion. Cell Mol Immunol. 2013;10:360–72.
 75. Wang JQ, Jeelall YS, Beutler B, Horikawa K, Goodnow CC. Consequences 
of the recurrent MYD88 (L265P) somatic mutation for B cell tolerance. J 
Exp Med. 2014;211:413–26.
 76. Ngo VN, Young RM, Schmitz R, Jhavar S, Xiao W, Lim KH, et al. Onco-
genically active MYD88 mutations in human lymphoma. Nature. 
2011;470:115–9.
 77. Ntoufa S, Vilia MG, Stamatopoulos K, Ghia P, Muzio M. Toll-like receptors 
signaling: a complex network for NF-kappaB activation in B-cell lymphoid 
malignancies. Semin Cancer Biol. 2016;39:15–25.
 78. Martínez-Trillos A, Pinyol M, Navarro A, Aymerich M, Jares P, Juan M, 
et al. Mutations in TLR/MYD88 pathway identify a subset of young 
chronic lymphocytic leukemia patients with favorable outcome. Blood. 
2014;123:3790–6.
 79. Link BK, Ballas ZK, Weisdorf D, Wooldridge JE, Bossler AD, Shannon M, 
et al. Oligodeoxynucleotide CpG 7909 delivered as intravenous infusion 
demonstrates immunologic modulation in patients with previously 
treated non-Hodgkin lymphoma. J Immunother. 2006;29:558–68.
 80. Leonard JP, Link BK, Emmanouilides C, Gregory SA, Weisdorf D, Andrey 
J, et al. Phase I trial of Toll-like receptor 9 agonist PF-3512676 with and 
following rituximab in patients with recurrent indolent and aggressive 
non-Hodgkin’s lymphoma. Clin Cancer Res. 2007;13:6168–74.
 81. Chauhan D, Singh AV, Brahmandam M, Carrasco R, Bandi M, Hideshima T, 
et al. Functional interaction of plasmacytoid dendritic cells with multiple 
myeloma cells: a therapeutic target. Cancer Cell. 2009;16:309–23.
 82. Cottini F, Anderson K. Novel therapeutic targets in multiple myeloma. Clin 
Adv Hematol Oncol. 2015;13:236–48.
 83. Ray A, Tian Z, Das DS, Coffman RL, Richardson P, Chauhan D, et al. A 
novel TLR-9 agonist C792 inhibits plasmacytoid dendritic cell-induced 
myeloma cell growth and enhance cytotoxicity of bortezomib. Leukemia. 
2014;28:1716–24.
 84. Abdelwahed RB, Cosette J, Donnou S, Crozet L, Ouakrim H, Fridman WH, 
et al. Lymphoma B-cell responsiveness to CpG-DNA depends on the 
tumor microenvironment. J Exp Clin Cancer Res. 2013;32:18.
 85. Weber JS, Zarour H, Redman B, Trefzer U, O’day S, van den Eertwegh 
AJ, et al. Randomized phase 2/3 trial of CpG oligodeoxynucleotide 
PF-3512676 alone or with dacarbazine for patients with unresectable 
stage III and IV melanoma. Cancer. 2009;115:3944–54.
 86. Leichman G, Gravenor D, Albert G, Schmalbach T. A TLR9 CpG immu-
nomodulator in combination with chemotherapy as treatment for 
advanced non-small cell lung cancer (NSCLS), a randomized, controlled 
phase II study. J Clin Oncol. 2004;22:7126.
 87. Jordan M, Waxman DJ. CpG-1826 immunotherapy potentiates chemo-
therapeutic and anti-tumor immune responses to metronomic cyclo-
phosphamide in a preclinical glioma model. Cancer Lett. 2016;373:88–96.
 88. Jahrsdörfer B, Weiner GJ. CpG oligodeoxynucleotides as immunotherapy 
in cancer. Update Cancer Ther. 2008;3:27–32.
 89. Mason KA, Neal R, Hunter N, Ariga H, Ang K, Milas L. CpG oligodeoxynu-
cleotides are potent enhancers of radio-and chemoresponses of murine 
tumors. Radiother Oncol. 2006;80:192–8.
 90. Milas L, Mason KA, Ariga H, Hunter N, Neal R, Valdecanas D, et al. CpG 
oligodeoxynucleotide enhances tumor response to radiation. Cancer Res. 
2004;64:5074–7.
 91. Mason KA, Ariga H, Neal R, Valdecanas D, Hunter N, Krieg AM, et al. Target-
ing toll-like receptor 9 with CpG oligodeoxynucleotides enhances tumor 
response to fractionated radiotherapy. Clin Cancer Res. 2005;11:361–9.
 92. Sohn WJ, Lee KW, Choi SY, Chung E, Lee Y, Kim TY, et al. CpG-oligodeoxy-
nucleotide protects immune cells from γ-irradiation-induced cell death. 
Mol Immunol. 2006;43:1163–71.
 93. Betting DJ, Yamada RE, Kafi K, Said J, van Rooijen N, Timmerman JM. 
Intratumoral but not systemic delivery of CpG oligodeoxynucleotide aug-
ments the efficacy of anti-CD20 monoclonal antibody therapy against B 
cell lymphoma. J Immunother. 2009;32:622–31.
 94. Warren TL, Dahle CE, Weiner GJ. CpG oligodeoxynucleotides enhance 
monoclonal antibody therapy of a murine lymphoma. Clin Lymphoma. 
2000;1:57–61.
 95. Wooldridge JE, Ballas Z. KriegAM, Weiner GJ. Immunostimulatory 
oligodeoxynucleotides containing CpG motifs enhance the efficacy of 
monoclonal antibody therapy of lymphoma. Blood. 1997;89:2994–8.
 96. Betting DJ, Hurvitz SA, Steward KK, Yamada RE, Kafi K, van Rooijen N, et al. 
Combination of cyclophosphamide, rituximab, and intratumoral CpG oli-
godeoxynucleotide successfully eradicates established B cell lymphoma. 
J Immunother. 2012;35:534–43.
